Q3 2023 Results
Company overview
Financial review
Conclusions
Appendix
References
Strong Q3 growth driven by performance from Kesimpta®,
EntrestoⓇ, KisqaliⓇ and PluvictoⓇ. Cosentyx® returns to growth
Q3 sales
GROWTH
Kesimpta
(ofatumumab)
Entresto
sacubitril/valsartan
Sales
USD million
Growth vs. PY
Growth vs. PY
CC
USD million
657
368
124%
1,485
350
31%
KISQALI
562
235
76%
ribociclib
PLUVICTO™
256
176
217%
Strong growth
(+41% cc);
SCEMBLIX'
106
65
157%
expected to continue
(asciminib)
LEQVIO
90
56
165%
Cosentyx
1,329
55
4%
(secukinumab)
ILARIS
(canakinumab)
335
63
24%
PROMACTA®
576
53
10%
(eltrombopag)
Xolair
Omalizumab
369
47
13%
JAKAVI
ruxolitinib
427
41
9%
Constant currencies (cc) is a non-IFRS measure; explanation of non-IFRS measures can be found on page 48 of Condensed Interim Financial Report. Unless otherwise noted, all growth rates refer to same period in PY.
5 Investor Relations | Q3 2023 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation